Octapharma
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-36
RECRUITING5
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO83%
Delay Index: of 6 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +29.0 months). See all sponsors →
Open Octapharma on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Newnorm NCT04640142 |
P3 | Active, not recruiting | Primary Immune Deficiency | 50 | 2026-11 (+64 mo) |
| OCTA-C1-INH NCT06361537 |
P3 | Recruiting | Acute Hereditary Angio Edema | 124 | 2026-12 (+12 mo) |
| Atenativ NCT04918173 |
P3 | Recruiting | Congenital Antithrombin Deficiency | 38 | 2026-12-01 (+29 mo) |
| Human plasma derived antithrombin NCT06096116 |
P3 | Recruiting | Acquired Antithrombin Deficiency | 120 | 2028-03 (+18 mo) |
| Panzyga NCT04929236 |
P3 | Recruiting | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy | 30 | 2028-12-31 (+43 mo) |
| Panzyga, 10% Intravenous Solution NCT07220915 |
P3 | Recruiting | Hypogammaglobulinemia; Autoimmune Conditions | 360 | 2029-12 |